WO1997040680A1 - Antioxidant compound - Google Patents
Antioxidant compound Download PDFInfo
- Publication number
- WO1997040680A1 WO1997040680A1 PCT/US1997/007037 US9707037W WO9740680A1 WO 1997040680 A1 WO1997040680 A1 WO 1997040680A1 US 9707037 W US9707037 W US 9707037W WO 9740680 A1 WO9740680 A1 WO 9740680A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bucindolol
- treatment
- pharmaceutically acceptable
- acceptable salt
- need
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 27
- 239000003963 antioxidant agent Substances 0.000 title abstract description 8
- 230000003078 antioxidant effect Effects 0.000 title abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 14
- FBMYKMYQHCBIGU-UHFFFAOYSA-N 2-[2-hydroxy-3-[[1-(1h-indol-3-yl)-2-methylpropan-2-yl]amino]propoxy]benzonitrile Chemical compound C=1NC2=CC=CC=C2C=1CC(C)(C)NCC(O)COC1=CC=CC=C1C#N FBMYKMYQHCBIGU-UHFFFAOYSA-N 0.000 claims description 23
- 229950005341 bucindolol Drugs 0.000 claims description 23
- 230000000302 ischemic effect Effects 0.000 claims description 16
- 210000000056 organ Anatomy 0.000 claims description 15
- 208000014674 injury Diseases 0.000 claims description 14
- 241000124008 Mammalia Species 0.000 claims description 12
- 230000004224 protection Effects 0.000 claims description 12
- 230000005961 cardioprotection Effects 0.000 claims description 11
- 230000008733 trauma Effects 0.000 claims description 11
- 230000000451 tissue damage Effects 0.000 claims description 10
- 231100000827 tissue damage Toxicity 0.000 claims description 10
- 230000004112 neuroprotection Effects 0.000 claims description 9
- 230000001590 oxidative effect Effects 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 8
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 7
- 208000010125 myocardial infarction Diseases 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 210000001519 tissue Anatomy 0.000 claims description 6
- 230000002490 cerebral effect Effects 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 230000002107 myocardial effect Effects 0.000 claims description 4
- 230000004792 oxidative damage Effects 0.000 claims description 4
- 230000001631 hypertensive effect Effects 0.000 claims description 3
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 210000005084 renal tissue Anatomy 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 description 13
- 230000003859 lipid peroxidation Effects 0.000 description 9
- 235000002639 sodium chloride Nutrition 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- -1 oxygen free radical Chemical class 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 5
- 230000003293 cardioprotective effect Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010063837 Reperfusion injury Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000003276 anti-hypertensive effect Effects 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 238000011360 adjunctive therapy Methods 0.000 description 3
- 102000015005 beta-adrenergic receptor activity proteins Human genes 0.000 description 3
- 108040006818 beta-adrenergic receptor activity proteins Proteins 0.000 description 3
- 210000000748 cardiovascular system Anatomy 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000000324 neuroprotective effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000002516 radical scavenger Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000010410 reperfusion Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical group 0.000 description 2
- 210000005227 renal system Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 238000004435 EPR spectroscopy Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 0 N#Cc1ccccc1*c1c[n]c2ccccc12 Chemical compound N#Cc1ccccc1*c1c[n]c2ccccc12 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
- 230000036459 cardiodepression Effects 0.000 description 1
- 229940045200 cardioprotective agent Drugs 0.000 description 1
- 239000012659 cardioprotective agent Substances 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 1
- 208000037974 severe injury Diseases 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 229910001428 transition metal ion Inorganic materials 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the present invention relates to a new medical use of, and method of treatment using, the compound of Formula I, as an oxygen radical scavenger, or as an antioxidant, for the protection of vital organs, particularly the organs of the cardiovascular system e.g. the heart, the central nervous system, and the renal system, from oxidative tissue damage.
- the present invention provides a new use for the compound of this invention for making pharmaceutical compositions useful in the prevention of organ reperfusion injury, particularly cardioprotection, that is protection of the cardiovascular system from traumatic and post-traumatic injury associated with myocardial infarction, neuroprotection, that is protection of the central nervous system from traumatic and post-traumatic injury associated with stroke, and renal protection.
- the present invention provides a new medical use for the compound of Formula I as an oxygen radical scavenger or as an antioxidant for the protection of vital organs from oxidative damage.
- the present invention provides a new use for the compound of this invention to make pharmaceutical compositions useful in the prevention of organ reperfusion injury, particularly useful in cardioprotection, neuroprotection and renal protection.
- the present invention also provides a method of treatment for prevention of oxidative tissue damage to organs afflicted with disease-induced ischemic trauma, particularly cardioprotection, neuroprotection and renal protection, in mammals comprising internally administering to a mammal, preferably a human, in need thereof an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.
- a mammal preferably a human
- the preferred pharmaceutically acceptable salt of the Formula I compound is the hydrochloric acid salt.
- Bucindolol which is 2-[2-hydroxy-3-[[2-(lH-indol-3-yl)-l,l- dimethylethyl]amino]propoxy]-benzonitrile, is the compound of Formula I and it has the following structure:
- Bucindolol may be used as its free base or as a pharmaceutically acceptable salt thereof.
- the preferred pharmaceutically acceptable salt is the hydrochloric acid salt.
- ischemic organ trauma as in acute myocardial infarction or stroke, a high proportion of ischemic organ cells become irreversibly damaged and necrotic, the extent of injury being dependent upon the length of time that the trauma, e.g. the arterial occlusion, persists.
- the protection of myocardial cells from such damage and necrosis during occlusion occurring during myocardial infarction and post- infarction reperfusion is essential to achieving the therapeutic goal of restoration of cardiac function; here and throughout this application this property is referred to by the term "cardioprotection" and its synonyms.
- central nervous system neurons The protection of the central nervous system neurons from such damage and necrosis during occlusion occurring in stroke and post-traumatic reperfusion is essential to achieving the therapeutic goal of restoration of neurological function; here and throughout this application this property is referred to by the term "neuroprotection" and its synonyms.
- ⁇ -adrenoceptor antagonists for instance propranolol
- ⁇ -adrenoceptor antagonists for instance propranolol
- they also often have undesireable side effects such as bradycardia, elevated disatolic blood pressure and total peripheral resistance cardiodepression.
- Bucindolol is effective as a cardioprotective agent at antihypertensive doses which unexpectedly minimize these consequences.
- the combination of ⁇ -adrenoceptor blocking and vasodilatory properties of Bucindolol provides cardioprotection during and after acute myocardial infarction.
- the compound of the present invention is especially useful in cardioprotection, that is, prevention of acute myocardial infarction, and reduction of morbidity resulting from the sequelae of myocardial infarction and reperfusion.
- the compound of the present invention is especially useful in neuroprotection, that is, prevention of stroke, and reduction of morbidity resulting from the sequelae of stroke.
- Bucindolol exhibits cardioprotection, and is especially useful for providing a beneficial cardioprotective effect by prevention of oxidative tissue damage in ischemic human myocardium; thus this compound has utility as adjunctive therapy following myocardial infarction.
- Chronic administration of this compound can both reduce the risk of acute myocardial infarction in individuals at risk thereof as well as provide adjunctive therapy by reducing the magnitude of oxidative tissue damage following an ischemic cardiac event. Because hypertensive individuals are at increased risk of stroke, the cardioprotective use of the present compound at appropriate dosing regimens in combination with antihypertensive therapy significantly reduces the risk of acute myocardial infarction, reinfarction, the area of infarcted tissue should reinfarction occur, and sudden cardiac death in such patients.
- Bucindolol exhibits neuroprotection, and is especially useful for protecting cerebral tissue from stroke and neurotrauma and for preventing oxidative tissue damage of ischemic human cerebral tissue following occurrence of an ischemic event such as stroke or cerebral trauma.
- chronic administration of this compound can both reduce the risk of cerebral ischemia or stroke in individuals at risk thereof as well as provide adjunctive therapy by reducing the magnitude of oxidative tissue damage following an ischemic cerebral event.
- the neuroprotective use of the present compound at appropriate dosing regimens in combination with antihypertensive therapy significantly reduces the risk of stroke, and the sequelae of stroke in such patients.
- Bucindolol is useful for cardioprotection, neuroprotection and renal protection in humans according to the present invention at dosages ranging from about 25-400 mg/day p.o.
- the present invention also provides a method of treatment for prevention of oxidative tissue damage to organs afflicted with disease-induced ischemic trauma in mammals comprising internally administering to a mammal, preferably a human, in need thereof an effective amount of Bucindolol, or a pharmaceutically acceptable salt thereof.
- the preferred pharmaceutically acceptable salt is the hydrochloric acid salt.
- Bucindolol may be conveniently prepared as described in GB Patent No. 2001633.
- compositions of Bucindolol for cardioprotective, neuroprotective and renal protective uses according to the present invention may be formulated as solutions or lyophilized powders for parenteral administration. Powders may be reconstituted by addition of a suitable diluent or other pharmaceutically acceptable carrier prior to use.
- the liquid formulation is generally a buffered, isotonic, aqueous solution. Examples of suitable diluents are normal isotonic saline solution, standard 5% dextrose in water or buffered sodium or ammonium acetate solution.
- Such formulation is especially suitable for parenteral administration, but may also be used for oral administration or contained in a metered dose inhaler or nebulizer for insufflation. It may be desirable to add excipients such as ethanol, polyvinyl-pyrrolidone, gelatin, hydroxy cellulose, acacia, polyethylene glycol, mannitol, sodium chloride or sodium citrate.
- these compounds may be encapsulated, tableted or prepared in a emulsion or syrup for oral administration.
- Pharmaceutically acceptable solid or liquid carriers may be added to enhance or stabilize the composition, or to facilitate preparation of the composition.
- Liquid carriers include syrup, peanut oil, olive oil, glycerin, saline, ethanol, and water.
- Solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, magnesium stearate or stearic acid, talc, pectin, acacia, agar or gelatin.
- the carrier may also include a sustained release material such as glyceryl monostearate or glyceryl distearate, alone or with a wax.
- the amount of solid carrier varies but, preferably, will be between about 20 mg to about 1 g per dosage unit.
- the pharmaceutical preparations are made following the conventional techniques of pharmacy involving milling, mixing, granulating, and compressing, when necessary, for tablet forms; or milling, mixing and filling for hard gelatin capsule forms.
- a liquid carrier When a liquid carrier is used, the preparation will be in the form of a syrup, elixir, emulsion or an aqueous or non-aqueous suspension.
- Such a liquid formulation may be administered directly p.o. or filled into a soft gelatin capsule.
- Bucindolol The antioxidant activity of Bucindolol can be determined using a standard lipid peroxidase assay. The details of this in vitro assay are found in Feuerstein, et al., J. Hypertension. 11 (Supp. 4): S41-48 (1993).
- the figure represents a dose-response relationship of the neuroprotective effect of Carvedilol and Bucindolol in vitro.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
A new antioxidant use of, and method of treatment using, a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
Description
ANTIOXIDANT COMPOUND
Field of the Invention
The present invention relates to a new medical use of, and method of treatment using, the compound of Formula I, as an oxygen radical scavenger, or as an antioxidant, for the protection of vital organs, particularly the organs of the cardiovascular system e.g. the heart, the central nervous system, and the renal system, from oxidative tissue damage. In particular, the present invention provides a new use for the compound of this invention for making pharmaceutical compositions useful in the prevention of organ reperfusion injury, particularly cardioprotection, that is protection of the cardiovascular system from traumatic and post-traumatic injury associated with myocardial infarction, neuroprotection, that is protection of the central nervous system from traumatic and post-traumatic injury associated with stroke, and renal protection.
Background of the Invention
Morbidity and mortality associated with disease-induced ischemic trauma of the vital organs, for instance as seen in acute myocardial infarction, represent major health problems in the developed world.
Considerable biochemical, physiological and pharmacological evidence supports the occurrence and importance of oxygen free radical -induced lipid peroxidation (LPO) in cardiac ischemia/reperfusion injury (Meerson, F. Z. et al., Basic Res. Cardiol. (1982) 77, 465-485; Downey, J. M., Ann. Rev. Physiol. ( 1990) 52, 487-504). It has been proposed that reoxygenation of ischaemic myocardium leads to generation of 02 and H2O2 within the tissue which can, in the presence of transition metal ions, become converted into highly-reactive hydroxyl radicals (OH) which initiate LPO, a radical chain reaction, leading to changes in cell membrane integrity and tissue injury (McCord, J. M., N. Engl. J. Med. (1985), 312, 159-163; McCord, J. M., Fed. Proc, (1987) 46, 2402; Kagan, V. E., Lipid Peroxidation in Biomembranes, (1988) CRC Press, Boca Raton Florida). Marked activation of LPO in experimental myocardial infarction, as well as reoxygenation following transitory ischemia, have been demonstrated (Meerson et al., 1982; Rao et al., Adv. Exp. Med. Biol., (1983) 161, 347-363). Exposure of myocytes or whole heart to oxidant- generating systems produced severe injury, including inactivation of the ATP-
dependent Ca"1""1" sequestering system of cardiac sarcoplasmic reticulum (Halliwell, B. and Gutteridge, J. M. C. Free Radicals in Biology and Medicine, 2d ed., ( 1989) Clarendon Press, Oxford, England, 442-444). A significant increase in plasma LPO levels has also been reported recently in patients with myocardial infarction, especially during the initial 48 hrs after an attack (Loeper et al., Clinica Chimica Acta, ( 1991 ) 196, 1 19-126). The importance of LPO and oxygen radicals in tissue damage associated with ischemia is further supported by the protective effect of natural and synthetic antioxidants such as vitamin E and the lazaroid U-74500A (Levitt, M.A., Clin. Res. (1991) 39, 265A) or antioxidant enzymes such as superoxide dismutase (SOD) and catalase in diverse ischemic models (for review see Halliwell and Gutteridge, 1989).
Given the high incidence of disease-induced ischemic trauma of the vital organs, in particular, of the cardiovascular system including the heart, of the central nervous system including the brain, and of the renal system, together with the high survival rate of patients suffering these traumas in the developed world, there is a great need for pharmaceutical agents which prevent the occurence of such traumas and which protect the vital organs of patients in post-traumatic recovery from organ ischemic reperfusion injury.
Summary of the Invention
In a first aspect, the present invention provides a new medical use for the compound of Formula I as an oxygen radical scavenger or as an antioxidant for the protection of vital organs from oxidative damage. In particular, the present invention provides a new use for the compound of this invention to make pharmaceutical compositions useful in the prevention of organ reperfusion injury, particularly useful in cardioprotection, neuroprotection and renal protection.
In a second aspect, the present invention also provides a method of treatment for prevention of oxidative tissue damage to organs afflicted with disease-induced ischemic trauma, particularly cardioprotection, neuroprotection and renal protection, in mammals comprising internally administering to a mammal, preferably a human, in need thereof an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof. In particular, the preferred pharmaceutically acceptable salt of the Formula I compound is the hydrochloric acid salt.
Detailed Description of the Invention
Bucindolol, which is 2-[2-hydroxy-3-[[2-(lH-indol-3-yl)-l,l- dimethylethyl]amino]propoxy]-benzonitrile, is the compound of Formula I and it has the following structure:
(i)
This compound is claimed in GB Patent No. 2001633 (the '633 patent). Reference should be made to said patent for its full disclosure, including the methods of preparing this compound. The entire disclosure of the '633 patent is incoφorated herein by reference.
In the present invention, Bucindolol may be used as its free base or as a pharmaceutically acceptable salt thereof. The preferred pharmaceutically acceptable salt is the hydrochloric acid salt.
During ischemic organ trauma, as in acute myocardial infarction or stroke, a high proportion of ischemic organ cells become irreversibly damaged and necrotic, the extent of injury being dependent upon the length of time that the trauma, e.g. the arterial occlusion, persists. The protection of myocardial cells from such damage and necrosis during occlusion occurring during myocardial infarction and post- infarction reperfusion is essential to achieving the therapeutic goal of restoration of cardiac function; here and throughout this application this property is referred to by the term "cardioprotection" and its synonyms. The protection of the central nervous system neurons from such damage and necrosis during occlusion occurring in stroke and post-traumatic reperfusion is essential to achieving the therapeutic goal of restoration of neurological function; here and throughout this application this property is referred to by the term "neuroprotection" and its synonyms.
While traditional β-adrenoceptor antagonists, for instance propranolol, have a significant cardioprotective effect, they also often have undesireable side effects such as bradycardia, elevated disatolic blood pressure and total peripheral resistance cardiodepression. However, Bucindolol is effective as a cardioprotective agent at antihypertensive doses which unexpectedly minimize these consequences. At antihypertensive doses the combination of β-adrenoceptor blocking and vasodilatory
properties of Bucindolol provides cardioprotection during and after acute myocardial infarction. It is believed that the cardioprotective effects of β-adrenoceptor antagonists at such dosages result from an improvement in the balance between myocardial oxygen supply and demand by reducing myocardial work, which occurs secondary to reductions in both heart rate and contractility.
We have recently discovered, by use of electron paramagnetic resonance (EPR) studies, that Bucindolol is an oxygen radical scavenger. We have also discovered that, as an oxygen scavenger, the above-described compound acts to inhibit LPO, and further that this compound is a suφrisingly effective protective agent in generally preventing a wide variety of disease states associated with oxidative tissue damage to the organs due to LPO following ischemic traumas. In particular, the compound of the present invention is especially useful in cardioprotection, that is, prevention of acute myocardial infarction, and reduction of morbidity resulting from the sequelae of myocardial infarction and reperfusion. Also, in particular, the compound of the present invention is especially useful in neuroprotection, that is, prevention of stroke, and reduction of morbidity resulting from the sequelae of stroke.
Bucindolol exhibits cardioprotection, and is especially useful for providing a beneficial cardioprotective effect by prevention of oxidative tissue damage in ischemic human myocardium; thus this compound has utility as adjunctive therapy following myocardial infarction. Chronic administration of this compound can both reduce the risk of acute myocardial infarction in individuals at risk thereof as well as provide adjunctive therapy by reducing the magnitude of oxidative tissue damage following an ischemic cardiac event. Because hypertensive individuals are at increased risk of stroke, the cardioprotective use of the present compound at appropriate dosing regimens in combination with antihypertensive therapy significantly reduces the risk of acute myocardial infarction, reinfarction, the area of infarcted tissue should reinfarction occur, and sudden cardiac death in such patients.
Bucindolol exhibits neuroprotection, and is especially useful for protecting cerebral tissue from stroke and neurotrauma and for preventing oxidative tissue damage of ischemic human cerebral tissue following occurrence of an ischemic event such as stroke or cerebral trauma. Thus, chronic administration of this compound can both reduce the risk of cerebral ischemia or stroke in individuals at risk thereof as well as provide adjunctive therapy by reducing the magnitude of oxidative tissue damage following an ischemic cerebral event. Because hypertensive individuals are at increased risk of stroke, the neuroprotective use of the present compound at appropriate dosing regimens in combination with antihypertensive
therapy significantly reduces the risk of stroke, and the sequelae of stroke in such patients.
Bucindolol is useful for cardioprotection, neuroprotection and renal protection in humans according to the present invention at dosages ranging from about 25-400 mg/day p.o.
The present invention also provides a method of treatment for prevention of oxidative tissue damage to organs afflicted with disease-induced ischemic trauma in mammals comprising internally administering to a mammal, preferably a human, in need thereof an effective amount of Bucindolol, or a pharmaceutically acceptable salt thereof. The preferred pharmaceutically acceptable salt is the hydrochloric acid salt.
Bucindolol may be conveniently prepared as described in GB Patent No. 2001633.
Pharmaceutical compositions of Bucindolol for cardioprotective, neuroprotective and renal protective uses according to the present invention may be formulated as solutions or lyophilized powders for parenteral administration. Powders may be reconstituted by addition of a suitable diluent or other pharmaceutically acceptable carrier prior to use. The liquid formulation is generally a buffered, isotonic, aqueous solution. Examples of suitable diluents are normal isotonic saline solution, standard 5% dextrose in water or buffered sodium or ammonium acetate solution. Such formulation is especially suitable for parenteral administration, but may also be used for oral administration or contained in a metered dose inhaler or nebulizer for insufflation. It may be desirable to add excipients such as ethanol, polyvinyl-pyrrolidone, gelatin, hydroxy cellulose, acacia, polyethylene glycol, mannitol, sodium chloride or sodium citrate.
Alternatively, these compounds may be encapsulated, tableted or prepared in a emulsion or syrup for oral administration. Pharmaceutically acceptable solid or liquid carriers may be added to enhance or stabilize the composition, or to facilitate preparation of the composition. Liquid carriers include syrup, peanut oil, olive oil, glycerin, saline, ethanol, and water. Solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, magnesium stearate or stearic acid, talc, pectin, acacia, agar or gelatin. The carrier may also include a sustained release material such as glyceryl monostearate or glyceryl distearate, alone or with a wax. The amount of solid carrier varies but, preferably, will be between about 20 mg to about 1 g per dosage unit. The pharmaceutical preparations are made following the conventional techniques of pharmacy involving milling, mixing, granulating, and compressing, when necessary, for tablet forms; or milling, mixing and filling for hard gelatin capsule forms. When a liquid carrier is used, the preparation will be in the form of a
syrup, elixir, emulsion or an aqueous or non-aqueous suspension. Such a liquid formulation may be administered directly p.o. or filled into a soft gelatin capsule.
The following examples are purely illustrative and are provided to teach how to use the compound of the present invention, but they are not intended to limit the scope of the present invention in any manner.
Biological Experimentals
The antioxidant activity of Bucindolol can be determined using a standard lipid peroxidase assay. The details of this in vitro assay are found in Feuerstein, et al., J. Hypertension. 11 (Supp. 4): S41-48 (1993).
The antioxidant protective effect of Bucindolol on cultured neurons is determined using the methods described in Stroke. 23: 1630-1636 (1992).
The figure represents a dose-response relationship of the neuroprotective effect of Carvedilol and Bucindolol in vitro. In this system, Bucindolol dose- dependently blocks oxygen radicals induced neruonal death at an IC50 = 1 lμM.
The above description fully discloses how to make and use the present invention. However, the present invention is not limited to the particular embodiments described hereinabove, but includes all modifications thereof within the scope of the following claims.
Claims
1. A method of treatment for prevention of oxidative tissue damage to organs afflicted with disease-induced ischemic trauma in mammals comprising internally administering to a mammal in need thereof an effective amount of Bucindolol, which is a compound of Formula I:
(i) or a pharmaceutically acceptable salt thereof.
2. A method of treatment for cardioprotection in mammals comprising internally administering to a mammal in need thereof an effective amount of Bucindolol, which is a compound of Formula I:
(i) or a pharmaceutically acceptable salt thereof.
3. A method of treatment for cardioprotection of human patients surviving an acute myocardial infarction, comprising internally administering to a patient in need thereof an effective dose of a pharmaceutical composition comprising Bucindolol or a pharmaceutically acceptable salt thereof, said treatment reducing the risk of oxidative damage to myocardial tissue.
4. A method of treatment for the cardioprotection of hypertensive patients at risk for myocardial infarction, comprising internally administering to a human patient in need thereof an effective dose of a pharmaceutical composition comprising Bucindolol or a pharmaceutically acceptable salt thereof.
5. A method of treatment for renal protection in mammals comprising internally administering to a mammal in need thereof an effective amount of Bucindolol, which is a compound of Formula I:
(i) or a pharmaceutically acceptable salt thereof.
6. A method of treatment for renal protection of human patients surviving renal failure, comprising internally administering to a patient in need thereof an effective dose of a pharmaceutical composition comprising Bucindolol or a pharmaceutically acceptable salt thereof, said treatment reducing the risk of oxidative damage to renal tissue.
7. A method of treatment for neuroprotection in mammals comprising internally administering to a mammal in need thereof an effective amount of Bucindolol, which is a compound of Formula I:
(i) or a pharmaceutically acceptable salt thereof.
8. A method of treatment for neuroprotection of human patients surviving a stroke, comprising internally administering to a patient in need thereof an effective dose of a pharmaceutical composition comprising Bucindolol or a pharmaceutically acceptable salt thereof, said treatment reducing the risk of oxidative damage to cerebral tissue.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP09539096A JP2000510110A (en) | 1996-04-29 | 1997-04-25 | Antioxidant compounds |
EP97922494A EP0907318A4 (en) | 1996-04-29 | 1997-04-25 | Antioxidant compound |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1647696P | 1996-04-29 | 1996-04-29 | |
US60/016,476 | 1996-04-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997040680A1 true WO1997040680A1 (en) | 1997-11-06 |
Family
ID=21777334
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/007037 WO1997040680A1 (en) | 1996-04-29 | 1997-04-25 | Antioxidant compound |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0907318A4 (en) |
JP (1) | JP2000510110A (en) |
WO (1) | WO1997040680A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5405863A (en) * | 1992-12-01 | 1995-04-11 | Smithkline Beecham Corporation | Antioxidant cardioprotective use of, and method of treatment using, hydroxycarbazole compounds |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4234595A (en) * | 1977-07-13 | 1980-11-18 | Mead Johnson & Company | 3-Indolyl-tertiary butylaminopropanols |
ZA938897B (en) * | 1992-12-01 | 1994-08-01 | Smithkline Beecham Corp | Antioxidant neuroprotective use of and method of treatment using hydroxycarbazole compounds |
-
1997
- 1997-04-25 JP JP09539096A patent/JP2000510110A/en active Pending
- 1997-04-25 WO PCT/US1997/007037 patent/WO1997040680A1/en not_active Application Discontinuation
- 1997-04-25 EP EP97922494A patent/EP0907318A4/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5405863A (en) * | 1992-12-01 | 1995-04-11 | Smithkline Beecham Corporation | Antioxidant cardioprotective use of, and method of treatment using, hydroxycarbazole compounds |
Non-Patent Citations (2)
Title |
---|
DATABASE OF BIOSIS ON STN, 91:299458, ANDERSON et al., "Long-Term 2 Year Beneficial Effects of Beta-Adrenergic Blockade With Bucindolol in Patients With Idiopathic Dilated Cardiomyopathy"; & J. AM. COLL. CARDIOL., 17(6), pages 1373-1381, 1991. * |
See also references of EP0907318A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP0907318A4 (en) | 2000-02-02 |
JP2000510110A (en) | 2000-08-08 |
EP0907318A1 (en) | 1999-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU675481B2 (en) | Antioxydant cardioprotective use of, and method of treatmentusing, hydroxycarbazole compounds | |
HU225534B1 (en) | Pharmaceutical compositions comprising mirtazapine and one or more selective serotonin reuptake inhibitors | |
EP1558256B1 (en) | Pyrroloquinoline quinone and a beta blocker for the treatment of ischemia or reperfusion injury | |
CA2411882A1 (en) | Solid valsartan pharmaceutical compositions | |
MXPA06014885A (en) | Association of a sinus current inhibitor if and a conversion enzyme inhibitor. | |
US20020107279A1 (en) | Antioxidant neuroprotective use of, and method of treatment using, hydroxycarbazole compounds | |
AU673882B2 (en) | Antioxidant neuroprotective use of, and method of treatment using, hydroxycarbazole compounds | |
WO2005084392A2 (en) | 4-methylpyrazole formulations for inhibiting ethanol intolerance | |
WO1997040680A1 (en) | Antioxidant compound | |
JP2957618B2 (en) | Cardioprotective pharmaceutical composition comprising amiodarone, a nitro derivative, especially isosorbitol dinitrate, and optionally a β-blocker | |
US4686225A (en) | Vinpocetine for pulmonary hemorrhage and edema | |
US20050267124A1 (en) | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors | |
EP2052735B1 (en) | Pharmaceutical composition and kit comprising anserine for rapidly reducing uric acid in blood | |
JPH0576925B2 (en) | ||
WO2000025773A1 (en) | Pharmaceutical combination of mildronate and enalapril | |
EP0474438A1 (en) | Method for preventing or treating cerebrovascular disease employing the ACE-inhibitor ceronapril | |
US4716177A (en) | Tolrestat for inhibition of weight gain | |
Jaffe | Use of intravenous diltiazem in patients with acute coronary artery disease | |
CN100584333C (en) | Pharmaceutical composition for treating liver disease | |
Yoshikawa et al. | Antioxidants in gastric mucosal injury | |
EP1753433A1 (en) | Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and pde v inhibitors | |
Mayrleitner | E047/1 | |
WO1992002224A1 (en) | Antiparkinson mao reversible inhibitor | |
JPH04503806A (en) | therapeutic agent | |
WO1996022096A1 (en) | Pharmaceutical compositions containing bisaramil inhibiting radical production and process for preparing same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1997922494 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1997922494 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997922494 Country of ref document: EP |